Secretary Sebelius and Other HHS Officials to Discuss New Federal Approach to Medical Countermeasures

--(BUSINESS WIRE)-- U.S. Department of Health and Human Services Secretary Kathleen Sebelius, along with other HHS officials, will release and discuss the conclusions of an examination of the federal government’s system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures.


  Press conference on new report reviewing the federal government’s medical countermeasures enterprise


Kathleen Sebelius, Secretary, U.S. Department of Health and Human Services

Dr. Nicole Lurie, HHS Assistant Secretary for Preparedness and Response

Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, NIH

Dr. Robin Robinson, Director, Biomedical Advanced Research and Development Authority, HHS

Dr. Margaret Hamburg, Commissioner, Food and Drug Administration

Dr. Thomas Frieden, Director, Centers for Disease Control and Prevention

Dr. Harold Varmus, Former co-chair, President’s Council of Advisors on Science and Technology (PCAST) and former co-chair, PCAST Influenza Vaccinology Working Group

Dr. Eric Lander, Co-chair, President’s Council of Advisors on Science and Technology (PCAST) and co-chair, PCAST Influenza Vaccinology Working Group



Thursday, August 19, 2010
Press Registration - 8:00 a.m. EDT
Program - 8:30 a.m. to 10:00 a.m. EDT


HHS Auditorium
First Floor, Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201


Passcode for media: 3254713
Passcode for listen only: 8541357

Note: All HHS press releases, fact sheets and other press materials are available at


HHS Press Office

KEYWORDS:   United States  North America  District of Columbia

INDUSTRY KEYWORDS:   Health  Public Policy/Government  Healthcare Reform  Medical Devices  Pharmaceutical  Public Policy  White House/Federal Government  Medical Supplies  General Health



Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.